All In Biotech

Drug Trial Radar · NCT06556966

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

A Phase Ⅰ, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Study to Assess the Safety, Tolerability, and Pharmacokinetics of LPM787000048 Maleate Sustained-release Tablet (LY03020) in Chinese Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Aug 19, 2024

Primary completion

Feb 13, 2025

Study completion Feb 13, 2025

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Aug 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.

Conditions

  • Schizophrenia
  • Alzheimer's Disease Psychosis

Interventions

  • LY03020Drug

    LY03020 for one single dose

  • PlaceboDrug

    Placebo for one single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events (AEs)Time frame: up to144 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing AnDing Hospital Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.